Clinical trial
Infliximab (Remicade) to Treat Dermatomyositis and Polymyositis
NCT00033891 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT00033891 |
|---|---|
| Title | Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dermatomyositis, Polymyositis |
| Intervention type | Drug |
| Interventions | Infliximab |
| Enrollment | 14 |
| Start date | Apr 10, 2002 |
| Primary completion | Jul 31, 2007 |
| Completion | May 20, 2010 |
| First posted | Apr 12, 2002 |
| Last update posted | Dec 3, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: